New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis…
Articles by Patrícia Silva, PhD
miRagen Therapeutics, Inc., a biopharmaceutical company dedicated to the development of pioneering therapies based on microRNAs, recently announced the…
Boehringer Ingelheim recently announced new positive data on the company’s FDA-approved therapy OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis…
The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile…
Genentech, a member of the Roche Group, recently presented two abstracts on the company’s product Esbriet (pirfenidone), an oral…
Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was one of…
The Pulmonary Fibrosis Foundation (PFF) recently announced that the number of scientific poster presentations on idiopathic pulmonary fibrosis (IPF)…
The Pulmonary Fibrosis Foundation (PFF) recently announced in a press release a five-year collaboration with Boehringer Ingelheim…
The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund…
The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium…